<DOC>
	<DOCNO>NCT00002904</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness ecteinascidin 743 treat adult advance solid tumor .</brief_summary>
	<brief_title>Ecteinascidin 743 Treating Adults With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose ( MTD ) ecteinascidin-743 ( ET-743 ) administer single intravenous infusion every 21 day adult solid tumor amenable standard therapy . II . Describe qualitative quantitative toxic effect ET-743 , study predictability , duration , intensity , onset , reversibility , dose-relationship toxic effect patient . III . Propose safe dose phase II study base MTD determine study . IV . Assess pharmacokinetics ET-743 different dose level . V. Document antitumor effect ET-743 patient . OUTLINE : This multicenter study . All patient receive ET-743 IV 3 hour every 21 day 4 course . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ET-743 maximum tolerate dose determine . Patients follow 1 month , every 3 month disease progression . PROJECTED ACCRUAL : A total 40 patient accrue study 12 month .</detailed_description>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor amenable standard therapy No evidence brain involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : ANC least 2,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 mg/dL Transaminases normal ( great 2.5 time normal liver metastasis ) Alkaline phosphatase normal ( great 2.5 time normal liver bone metastasis ) No history chronic liver disease , e.g. , chronic active hepatitis , cirrhosis Renal : Creatinine great 1.4 mg/dL Creatinine clearance least 60 mL/min Other : No active bacterial infection ( e.g. , abscess ) fistulae No grade 2 bad neurotoxicity No concurrent medical condition precludes treatment No history alcoholism , drug addiction , psychotic disorder Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Colonystimulating factor allow specific indication At least 4 week since prior biologic therapy , immunotherapy , growth factor Chemotherapy : No prior intensive chemotherapy bone marrow stem cell support At least 4 week since chemotherapy ( 6 week since nitrosoureas , mitomycin , highdose carboplatin ) Endocrine therapy : Not specify Radiotherapy : At least 4 week since radiotherapy Concomitant palliative local radiotherapy allow exist lesion Surgery : Recovered prior surgery Other : No concurrent investigational drug Concurrent prophylactic antiemetic allow first therapy course</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>